LONDON, UK: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Pyxis Oncology Inc., has announced the pricing of its initial public offering of 10.5 million shares of common stock at a public offering price of $16 per share for aggregate gross…